Metsera, Inc./$MTSR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Metsera, Inc.
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
Ticker
$MTSR
Sector
Primary listing
Employees
107
Headquarters
Website
Metsera, Inc. Metrics
BasicAdvanced
$5.6B
-
-$5.89
-
-
Price and volume
Market cap
$5.6B
52-week high
$54.47
52-week low
$12.30
Average daily volume
2.8M
Financial strength
Current ratio
5.259
Quick ratio
5.189
Long term debt to equity
0.072
Total debt to equity
0.237
Interest coverage (TTM)
-665.80%
Profitability
EBITDA (TTM)
-223.687
Effective tax rate (TTM)
2.78%
Management effectiveness
Valuation
Price to book
12.37
Price to tangible book (TTM)
15.86
Price to free cash flow (TTM)
-15.533
Free cash flow yield (TTM)
-6.44%
Free cash flow per share (TTM)
-3.411
Growth
Bulls say / Bears say
MET-097i delivered an average weight loss of 11.3% in a mid-stage trial, showing strong results compared to current GLP-1 therapies. (Reuters)
Early-stage results for MET-233i indicated a potentially best-in-class profile, highlighting differentiation for its amylin analog candidate. (Reuters)
Pfizer’s proposed buyout values Metsera at up to $7.3 billion, a 42.5% premium to its pre-deal share price, confirming the strategic importance of its obesity pipeline. (Reuters)
Metsera’s lead candidates are still in early-stage development and have no approved products, signaling that commercial revenue is unlikely before the late 2020s. (Reuters)
The acquisition’s contingent value rights of up to $22.50 per share depend on meeting milestones and getting regulatory approvals, which introduces both execution and valuation risk. (Reuters)
Strong competition from GLP-1 leaders Novo Nordisk and Eli Lilly may put pressure on market share and pricing for Metsera’s future therapies. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Metsera, Inc. News
AllArticlesVideos
IP Group: Metsera deal highlights hidden value, say analysts
Proactive Investors1 week ago
IP Group shares climb 9% on potential royalties from Pfizer's $7.3bn Metsera deal
Proactive Investors1 week ago
Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug
CNBC3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Metsera, Inc. stock?
Metsera, Inc. (MTSR) has a market cap of $5.6B as of October 22, 2025.
What is the P/E ratio for Metsera, Inc. stock?
The price to earnings (P/E) ratio for Metsera, Inc. (MTSR) stock is 0 as of October 22, 2025.
Does Metsera, Inc. stock pay dividends?
No, Metsera, Inc. (MTSR) stock does not pay dividends to its shareholders as of October 22, 2025.
When is the next Metsera, Inc. dividend payment date?
Metsera, Inc. (MTSR) stock does not pay dividends to its shareholders.
What is the beta indicator for Metsera, Inc.?
Metsera, Inc. (MTSR) does not currently have a Beta indicator.